Genomic Health (NASDAQ: GHDX) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitabiliy and earnings.
Valuation and Earnings
This table compares Genomic Health and Zynerba Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Genomic Health||$330.95 million||3.35||-$188,999.00||($0.24)||-134.49|
|Zynerba Pharmaceuticals||N/A||N/A||-$26.59 million||($2.68)||-6.70|
Genomic Health has higher revenue and earnings than Zynerba Pharmaceuticals. Genomic Health is trading at a lower price-to-earnings ratio than Zynerba Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares Genomic Health and Zynerba Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
89.5% of Genomic Health shares are held by institutional investors. Comparatively, 30.4% of Zynerba Pharmaceuticals shares are held by institutional investors. 47.0% of Genomic Health shares are held by company insiders. Comparatively, 10.0% of Zynerba Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of current recommendations for Genomic Health and Zynerba Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Genomic Health presently has a consensus target price of $31.83, suggesting a potential downside of 1.38%. Zynerba Pharmaceuticals has a consensus target price of $32.25, suggesting a potential upside of 79.57%. Given Zynerba Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Zynerba Pharmaceuticals is more favorable than Genomic Health.
Volatility & Risk
Genomic Health has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Zynerba Pharmaceuticals has a beta of 5.17, indicating that its share price is 417% more volatile than the S&P 500.
Genomic Health beats Zynerba Pharmaceuticals on 7 of the 12 factors compared between the two stocks.
Genomic Health Company Profile
Genomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.
Zynerba Pharmaceuticals Company Profile
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/genomic-health-ghdx-and-zynerba-pharmaceuticals-zyne-head-to-head-comparison/1925599.html
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.